Literature DB >> 2865146

Central nervous system mechanisms in blood pressure control.

A D Struthers, C T Dollery.   

Abstract

Much of our knowledge about the CNS control of blood pressure is derived from animal studies using techniques such as intracerebroventricular administration of drugs, stereotactic ablation of specific brain nuclei, and biochemical analysis of these nuclei. These methods have identified numerous specific brain nuclei in the brain stem and a meshwork of interconnecting neurones involved in cardiovascular control. The main neurotransmitter involved is noradrenaline but recent interest has focused on several laterally situated nuclei which are capable of synthesizing adrenaline. Centrally acting antihypertensive drugs are thought to act by stimulating central alpha 2-adrenoceptors either by the parent drug itself (clonidine) or via the formation of an active metabolite (alpha-methyldopa). This leads to decreased peripheral sympathetic activity and a hypotensive response but the latter is often attained at the expense of central side-effects such as drowsiness or dry mouth. The mechanism of the antihypertensive effect of beta-blockers remains uncertain although the balance of evidence is against a central effect. The central administration of propranolol causes decreased peripheral sympathetic activity in animals, but plasma catecholamine levels are little altered by beta-blockers in man. In equipotent antihypertensive doses, central alpha-agonists cause a much greater reduction in plasma noradrenaline than beta-blockers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2865146     DOI: 10.1007/bf00543703

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  57 in total

1.  Reduction in sympathetic nervous activity as a mechanism for hypotensive effect of propranolol.

Authors:  P J Lewis; G Haeusler
Journal:  Nature       Date:  1975-07-31       Impact factor: 49.962

2.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

3.  Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy.

Authors:  R R Miller; H G Olson; E A Amsterdam; D T Mason
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

4.  Changes in blood pressure, heart rate, and plasma noradrenaline concentration after sudden withdrawal of propranolol.

Authors:  T J Maling; C T Dollery
Journal:  Br Med J       Date:  1979-08-11

5.  Adrenaline-forming enzyme in brainstem: elevation in genetic and experimental hypertension.

Authors:  J M Saavedra; H Grobecker; J Axelrod
Journal:  Science       Date:  1976-02-06       Impact factor: 47.728

6.  Comparison of fentanyl and halothane supplementation to general anaesthesia on the stress response to upper abdominal surgery.

Authors:  B C Campbell; R K Parikh; A Naismith; D Sewnauth; J L Reid
Journal:  Br J Anaesth       Date:  1984-03       Impact factor: 9.166

7.  Propranolol rebound--a retrospective study.

Authors:  R A Shiroff; J Mathis; R Zelis; D W Schneck; J D Babb; D M Leaman; A H Hayes
Journal:  Am J Cardiol       Date:  1978-04       Impact factor: 2.778

8.  Propranolol withdrawal and thyroid hormones in patients with essential hypertension.

Authors:  B O Kristensen; E Steiness; J Weeke
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

9.  Withdrawal of guanfacine after long-term treatment in essential hypertension. Observations on blood pressure and plasma and urinary noradrenaline.

Authors:  C Zamboulis; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

10.  Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man.

Authors:  P E Cryer; R A Rizza; M W Haymond; J E Gerich
Journal:  Metabolism       Date:  1980-11       Impact factor: 8.694

View more
  3 in total

Review 1.  Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Small GTPases       Date:  2014-10-31

2.  The effect of dietary n-6 and n-3 polyunsaturated fatty acids on blood pressure and tissue fatty acid composition in spontaneously hypertensive rats.

Authors:  Y Watanabe; Y S Huang; V A Simmons; D F Horrobin
Journal:  Lipids       Date:  1989-07       Impact factor: 1.880

3.  Neuroendocrine humoral and vascular components in the pressor pathway for brain angiotensin II: a new axis in long term blood pressure control.

Authors:  John M Hamlyn; Cristina I Linde; Junjie Gao; Bing S Huang; Vera A Golovina; Mordecai P Blaustein; Frans H H Leenen
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.